Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

By Sally Robertson, B.Sc.Jul 6 2021

Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection.

The spike protein is the main surface structure the virus uses to infect host cells and a primary target of neutralizing antibodies following SARS-CoV-2 vaccination or natural infection. The receptor-binding domain (RBD) of this spike mediates the initial stage of infection when it binds to the host cell receptor angiotensin-converting enzyme 2 (ACE2).  

The team from La Jolla Institute for Immunology in California found that a low dose (25 µg) of mRNA-1273 elicited durable anti-spike antibody, CD4+ and CD8+ T cell responses that were comparable in magnitude to those elicited by natural infection.

Daniela Weiskopf and colleagues also report that individuals who had pre-existing cross-reactive CD4+ T cell memory had increased CD4+ T cell and antibody responses to the vaccine, pointing to the biological relevance of SARS-CoV-2 cross-reactive CD4+ T cells.

A pre-print version of the research paper is available on the medRxiv* server, while the article undergoes peer review.

Study: Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing cross-reactive T cell memory. Image Credit: NIAID

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The durability of vaccine-induced immunity remains unknown

Moderna’s mRNA-1273 vaccine, which encodes the full-length SARS-CoV-2 spike protein, has been shown to be highly effective at preventing COVID-19.

However, the durability of the immunity induced by mRNA-based COVID-19 vaccines remains a major unknown.

Both Pfizer-BioNTech and Moderna have reported a protective immunity of around 90% lasting for six months following a second vaccination.

However, the underlying mechanisms of immunity remain unclear, and it is not known whether those mechanisms change as the immune response develops.

“Direct measurements of immune memory compartments in humans are necessary to provide insights into these important topics,” says Weiskopf and colleagues.

Comparison of vaccine- and infection-induced immune memory is valuable

The comparison of vaccine-generated and infection-induced immune memory is of value, since studies have shown that natural immunity is between 93% and 100% protective against symptomatic re-infection for 7 to 8 months

“It is unknown whether immune memory to mRNA1273 vaccine months after immunization is similar or different to memory generated by SARS-CoV-2 infection,” write the researchers.

Furthermore, pre-existing cross-reactive memory CD4+ T cells have previously been shown to recognize SARS-CoV-2 in vitro, and there is intense interest in whether these cells are biologically relevant in vivo.

Weiskopf and colleagues suggest that a low level of antigen exposure may be more sensitive in detecting any impact of cross-reactive memory on immune responses.

What did the current study involve?

The researchers assessed vaccine-specific CD4+ T cell, CD8+ T cell, binding antibody, and neutralizing antibody responses to a low dose (25µg) of the Moderna mRNA-1273 vaccine among 35 participants of an open-label phase 1 trial who were immunized on day one and day 29.

Overall, two 25µg vaccine doses induced significant anti-spike immunoglobulin G (IgG) antibodies, anti-spike RBD IgG and neutralizing antibody responses. These responses were maintained in 88% to 100% of vaccinees for at least six months following the second immunization and resembled responses observed among convalescent COVID-19 cases.

Spike-specific CD4+ T cell responses were observed in 97% of participants following the first vaccination and all participants following the second vaccination. These responses were maintained for at least six months following the second vaccination.

Assessing spike-specific CD4+ T cell functionality

To assess functionality, the researchers measured T follicular helper (TFH) cell differentiation and cytokine production by the vaccine-generated spike-specific CD4+ T cells.

“TFH cells are the specialized subset of CD4+ T cells required for B cell help and are critical for the generation of neutralizing antibodies in most condition,” explains the team.

Spike-specific circulating TFH (cTFH) cells were detected in 94% of individuals overall and spike-specific memory cTFH cells were still detectable in 63% of vaccinees six months after the second vaccination.

Cytokine-producing spike-specific CD4+ T cells were observed in 94% and 100% of individuals following the first and second vaccination, respectively, and were maintained for at least six months in 97% following the second vaccination.

What about CD8+ T cells?

The team also reports that spike-specific CD8+ T cells were detected in 88% of participants, which is equivalent to the CD8+ T cell response rate among COVID-19 cases.

Spike-specific memory CD8+ T cells were detectable for at least 6 months in 67% of individuals after the second vaccination – a memory response rate that is not dissimilar to that observed among COVID-19 cases.

“These vaccine immune response data demonstrate that spike antibody, CD4+ and CD8+ T cell responses generated by 25µg mRNA-1273 vaccination are multifunctional, durable, and comparable in magnitude to those induced by natural infection,” writes Weiskopf and colleagues.

Pre-existing spike cross-reactive memory CD4+ T cells enhanced immune memory responses

On day one, prior to vaccination, spike-specific memory CD4+ T cells were detected in 49% of participants, suggesting the presence of pre-existing spike cross-reactive memory CD4+ T cells.

These individuals with pre-existing cross-reactive CD4+ T cell memory had higher levels of spike-specific CD4+ T cells and higher titers of neutralizing antibodies six months following the second vaccine dose, compared with individuals who did not have pre-existing cross-reactive cells.

Vaccine-induced immune memory was comparable to that induced by natural infection

Weiskopf and colleagues say the findings demonstrate of the potential of RNA vaccines to generate immune memory, including at lower doses.

“The mRNA-1273 vaccine induces a durable and functional T cell and antibody response that is comparable to natural infection,” they write. “Furthermore, the immune responses were significantly enhanced by the presence of pre-existing cross-reactive CD4+ T cell memory.”

The researchers say it is plausible that the presence of cross-reactive memory T cells could accelerate the speed and magnitude of CD4+ T cell and antibody responses to SARS-CoV-2 infection.

“Early T cell responses have been linked to less severe clinical outcomes,” notes the team.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources